1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

Effient is an antiplatelet blood thinner that inhibits the P2Y12 receptor. Inhibition of P2Y12 blocks key signaling events in platelets that lead to coagulation. Effient is supplied as 10mg tablets and is administered as a 60mg loading dose during the acute phase of ACS, and as a once-daily 10mg maintenance dose during the chronic phase of ACS for the first year following an ACS event. Effient is indicated to reduce the occurrence of CV events in ACS patients managed with PCI.

Scope

- Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Aricept for the top seven countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for ACS
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Aricept performance
- Obtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table Of Contents

Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 18
3.1.3 Prognosis 19
3.1.4 Quality of Life 20
3.2 Symptoms 20
4 Disease Management 22
4.1 Treatment Overview 22
5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 29
6 Effient (prasugrel) 34
6.1 Overview 34
6.2 Efficacy 36
6.3 Safety 37
6.4 SWOT Analysis 38
6.5 Forecast 38
7 Appendix 40
7.1 Bibliography 40
7.2 Abbreviations 45
7.3 Methodology 49
7.4 Forecasting Methodology 49
7.4.1 Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population 49
7.4.2 Diagnosed Acute Coronary Syndrome Patients 50
7.4.3 Percent Drug-Treated Patients 51
7.4.4 General Pricing Assumptions 51
7.4.5 Individual Drug Assumptions 53
7.4.6 Generic Erosion 53
7.5 Physicians and Specialists Included in this Study 54
7.6 About the Authors 57
7.6.1 Author 57
7.6.2 Reviewer 57
7.6.3 Global Head of Healthcare 58
7.7 About GlobalData 59
7.8 Disclaimer 59

1.1 List of Tables

Table 1: Antiplatelet Agents that Inhibit Platelet Activation 16
Table 2: Anticoagulants that Inhibit the Coagulatory Cascade 16
Table 3: Symptoms of Acute Coronary Syndrome 21
Table 4: Treatment Guidelines for Acute Coronary Syndromes (UA, NSTEMI, and STEMI) 25
Table 5: Most Prescribed Drugs for ACS by Class in the Global Markets, 2014 27
Table 6: Leading Treatments for Acute Coronary Syndrome, 2014 33
Table 7: Product Profile - Effient (prasugrel) 36
Table 8: Effient (prasugrel) SWOT Analysis, 2014 38
Table 9: Global Sales Forecasts ($m) for Effient, 2013-2023 39
Table 10: Price Sources and Calculations, by Country 52
Table 11: Physicians Surveyed, By Country 56

1.2 List of Figures

Figure 1: The ACS Timeline and the Scope of GlobalData's ACS Report and Forecast 14
Figure 2: Progression of Coronary Artery Disease, Atherosclerotic Plaque Rupture, Thrombosis, and Acute Coronary Syndrome 15
Figure 3: Platelet and Coagulatory Factors Implicated in Thrombosis 17
Figure 4: Electrocardiography in the Diagnosis of ACS 18

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.